RTP Mobile Logo
RTP On Demand: Current Controversies and Emerging Data Sets in Follicular Lymphoma and Chronic Lymphocytic Leukemia
Released August 2013

Proceedings from a video interview with Dr Jonathan Friedberg on follicular lymphoma and chronic lymphocytic leukemia including data review, case-based discussions and downloadable slides. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

    OVERVIEW OF ACTIVITY
    Hematologic oncology and related blood disorders are some of the most rapidly evolving fields in all of medicine. Results presented at major conferences from a plethora of ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care, the practicing hematologist-oncologist must be well informed of these advances. To bridge the gap between research and patient care, this program uses one-on-one discussion with Dr Jonathan Friedberg about treatment controversies and the integration of key data sets recently presented into the practical management of follicular lymphoma and chronic lymphocytic leukemia.

    LEARNING OBJECTIVES

    • Appraise recent data on therapeutic advances and changing practice standards in follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL), and integrate this information, as appropriate, into current clinical care.
    • Identify patients with FL who may benefit from maintenance systemic treatment.
    • Recall new data with investigational agents demonstrating promising activity in FL.
    • Apply the results of emerging clinical research to the selection of optimal systemic therapy for patients with newly diagnosed and relapsed or refractory CLL.
    • Identify ongoing clinical trials evaluating innovative investigational approaches for FL and CLL, and obtain consent from appropriate patients for study participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue


    HOW TO USE THIS CME ACTIVITY
    This activity consists of a video component. The participant should watch the video.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and his spouse/partner) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Jonathan W Friedberg, MD, MMSc
    Samuel Durand Professor of Medicine
    Director, Wilmot Cancer Center
    University of Rochester
    Rochester, New York

    Advisory Committee: Genentech BioOncology; Data and Safety Monitoring Board: Lilly USA LLC.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Genentech BioOncology/Biogen Idec.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2013
    Expiration date: August 2014

Acknowledge and close

Watch video
(WIFI is recommended for best performance):

BRIGHT and StiL NHL1-2003 studies of bendamustine/rituximab versus rituximab/ chemotherapy in NHL
Rituximab schedule and maintenance in FL
Rituximab combined with lenalidomide (R squared) in untreated lymphoma
Type II anti-CD20 monoclonal antibody obinutuzumab in CLL
Novel agents in FL and CLL: BTK inhibitors
Targeted therapies in lymphomas and CLL: BTK, Syk and PI3Kδ inhibitors
Case 1: 59-year-old woman with Stage IE, Grade 3A FL
Case 2: 48-year-old woman diagnosed 10 years ago with FL
Case 3: 62-year-old man with Grade 1 FL and Stage IIA colon adenocarcinoma
Case 4: 60-year-old man with asymptomatic progression of CLL